Renaissance Technologies LLC Decreases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Renaissance Technologies LLC decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 69.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,100 shares of the medical equipment provider's stock after selling 252,931 shares during the quarter. Renaissance Technologies LLC owned about 0.16% of Lantheus worth $9,760,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the 3rd quarter worth $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the 4th quarter valued at about $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus during the 4th quarter worth approximately $37,000. UMB Bank n.a. increased its holdings in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Down 1.0 %

Lantheus stock traded down $1.05 during trading hours on Tuesday, hitting $99.57. The stock had a trading volume of 813,226 shares, compared to its average volume of 953,863. The business's 50 day simple moving average is $96.11 and its 200-day simple moving average is $95.36. Lantheus Holdings, Inc. has a one year low of $62.59 and a one year high of $126.89. The stock has a market cap of $6.82 billion, a price-to-earnings ratio of 16.57 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,109 shares of company stock worth $6,016,046. Company insiders own 2.00% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. Finally, B. Riley reduced their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.